ArticleBMC medical imaging2025
Differentiating between adrenocortical carcinoma and pheochromocytoma by a CT-based radiomics model: a multicenter retrospective study.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The diagnostic value of native and early post-contrast CT attenuation in differentiating benign from potentially malignant adrenal lesions.International urology and nephrology · 2026Observational
- AI-enabled precision evaluation of adrenal masses: radiomics, deep learning, and explainable imaging biomarkers.Frontiers in endocrinology · 2026Review
- An interpretableFrontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundAdrenocortical carcinoma (ACC), a rare and highly malignant adrenal gland tumor, exhibits computed tomography (CT) characteristics that resemble those of the less malignant pheochromocytoma (PHEO). While biochemical evaluation is widely accepted for differentiating between ACC and PHEO, non-functioning tumors remain a diagnostic challenge. The similarity in CT imaging and atypical hormone levels can lead to suboptimal accuracy in diagnosis, leading to inappropriate clinical interventions. This study aims to differentiate between large (≥ 4 cm) ACC and PHEO with radiomics features based on contrast-enhanced CT.
methodsIn this retrospective study, 158 patients who received pathological diagnoses of ACC or PHEO between January 2011 and September 2023 were enrolled from three institutions. Radiomics features were extracted from different phases of contrast-enhanced CT and then selected by a two-step procedure. The radiomics model was developed in a cohort of 109 patients from Institution 1, then the model performance was evaluated in the external test cohort of 49 patients from Institutions 2 and 3. The area under the receiver operating characteristic curve (AUC) of the radiomics model was compared with two radiologists using the DeLong test. Hormone testing results were collected to determine the presence of excess cortisol or catecholamines. SHapley Additive exPlanations (SHAP) was used to improve the interpretability of the radiomics model.
resultsWe developed and evaluated a radiomics model consisting of ten selected CT-based radiomics features. In the external test cohort, the proposed radiomics model achieved high accuracy (86%), specificity (88%), and sensitivity (81%) in differentiating between ACC and PHEO and outperformed 2 radiologists (AUC 0.920 vs. 0.786, 0.629). This radiomics model showed strong capabilities in differentiating biochemically negative ACC and PHEO (with an accuracy of 80%). Moreover, its performance remained consistent even when cortisol and catecholamine levels were simultaneously elevated. Furthermore, SHAP provided quantitative explanations for the radiomics model and visualized the diagnostic process.
conclusionsThe interpretable CT-based radiomics model outperforms radiologists in differentiating between ACC and PHEO, especially when hormone testing results are atypical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.